Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of NICE condition severity ratings on the accessibility of drugs for those with secondary breast cancer.

he latest data for technology appraisals published up until the end of September 2025 shows that the National Institute for Health and Care Excellence (NICE) has recommended a greater proportion of medicines for advanced cancer since the severity modifier was introduced compared with NICE’s previous methods. The proportion of positive decisions for advanced cancer treatments since the severity modifier was introduced is 85% compared with 69% using NICE’s previous methods. Since the severity modifier was introduced, NICE has recommended all but one treatment for advanced breast cancer where the company has participated fully in the appraisal. The only treatment for advanced breast cancer that NICE has not been able to recommend in final guidance since the severity modifier was introduced is Enhertu.